Clinical

Dataset Information

0

Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer

ABSTRACT: RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory metastatic colorectal cancer.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2007775 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer
| 2004705 | ecrin-mdr-crc
Clinical Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer
| 2002897 | ecrin-mdr-crc
Clinical Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
| 2005109 | ecrin-mdr-crc
Clinical Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
| 2005072 | ecrin-mdr-crc
Clinical Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
| 2003478 | ecrin-mdr-crc
Clinical Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer
| 2006798 | ecrin-mdr-crc
Clinical Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
| 2006956 | ecrin-mdr-crc
Clinical Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
| 2006690 | ecrin-mdr-crc
Clinical Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
| 2008497 | ecrin-mdr-crc
Clinical Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
| 2003442 | ecrin-mdr-crc